Beta Bionics, Inc. President and CEO Sean Saint filed a Form 4 on September 4, 2026, disclosing the sale of 5,641 shares of common stock on September 3, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Sean Saint, President and CEO of Beta Bionics, Inc. (NASDAQ:BBNX), also identified as a Director.
  • Shares sold: 5,641 shares of common stock disposed of (transaction code S) on September 3, 2026.
  • Weighted average price: $20.0778 per share, with individual prices ranging between $20.00 and $20.1696.
  • Plan basis: The sale was executed pursuant to a Rule 10b5-1 plan adopted on September 5, 2025.
  • Remaining ownership: 398,429 shares of common stock held directly following the reported transaction.

Sean Saint's Share Sale Details and Remaining Stake in Beta Bionics

According to the filing, Sean Saint, who serves as President, CEO, and Director of Beta Bionics, Inc. (NASDAQ:BBNX), sold 5,641 shares of the company's common stock on September 3, 2026. The transaction carried code "S," indicating a sale. The filing notes that the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as indicated by the checked box on the form.

The filing discloses that the weighted average sale price for the reported transaction was $20.0778 per share, and that the range of individual sale prices fell between $20.00 and $20.1696. The filing states: "Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided." The Rule 10b5-1 plan under which the shares were sold was adopted on September 5, 2025, according to the filing's explanation of responses.

Following the reported sale, the filing shows Saint directly held 398,429 shares of Beta Bionics common stock. No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Stephen Feider as Attorney-in-Fact on September 4, 2026.

What Was Disclosed

The filing disclosed the sale of 5,641 shares of Beta Bionics common stock by President and CEO Sean Saint on September 3, 2026, at a weighted average price of $20.0778, under a pre-existing Rule 10b5-1 plan, leaving him with 398,429 shares held directly.